ICAAC is traditionally a venue for presenting data on new drugs and new drug combinations. Program Committee member Karen Bush, David Shlaes, MD, PhD, Anti-Infectives Consulting, Stonington, CT, and J. Kevin Judice, Ph.D., CEO, Achaogen, present an overview of new drugs and clinical trial data being presented at this year's meeting, highlighting the more promising compounds and discussing the overall state of the antibiotic pipeline.
ICAAC is traditionally a venue for presenting data on new drugs and new drug combinations. Program Committee member Karen Bush, David Shlaes, MD, PhD, Anti-Infectives Consulting, Stonington, CT, and J. Kevin Judice, Ph.D., CEO, Achaogen, present an overview of new drugs and clinical trial data being presented at this year's meeting, highlighting the more promising compounds and discussing the overall state of the antibiotic pipeline.
by ccondayan